Self-priming effect of luteinizing hormone-human chorionic gonadotropin (hCG) upon the biphasic testicular response to exogenous hCG. I. Serum testosterone profile.
The present study was conducted to investigate whether the early (2-8 h) testicular response to a single dose of exogenous hCG depends on previous exposure to LH activity. Four different groups of subjects were studied: 1) four normal adult men [Tanner stage-G5 (T-G5)] and one late pubertal subject (T-G4); 2) normal prepubertal (T-G1) and early- and midpubertal boys (T-G2 and T-G3) (n = 4-6 each); 3) five patients with hypogonadotropic hypogonadism (HH); and 4) two patients with the complete form of the androgen insensitivity syndrome. Each subject received an im injection of hCG (40 IU/kg) on day 1 and blood samples were drawn before and 1-8, 24, 48, and 72 h after injection. At 96 h, a second dose of hCG was given (80 IU/kg) and blood samples were obtained at the same times as after the first hCG dose. Serum testosterone (T) was measured by RIA. The first dose of hCG evoked a biphasic response of serum T in groups T-G2 to T-G5 as well as in the two patients with the complete form of the androgen insensitivity syndrome. The early peak was at 2-7 h, whereas the late T peak was at 48-72 h after injection. In T-G1 children and in patients with HH, the early response did not occur [T-G1, from 129 +/- 43 (SEM) to 288 +/- 127 pg/ml (P greater than 0.05); HH, 79 +/- 18 to 107 +/- 12 (P greater than 0.05) pg/ml], and the late peak was attenuated as compared with the pubertal boys. There were not significant differences in the responses of the T-G1 and the HH groups. After the second dose, all groups had biphasic T responses, although they varied in magnitude. These results demonstrate that previous exposure to LH activity is an obligatory prerequisite for the early peak of the hCG-mediated biphasic testicular response, and that a single dose of hCG has a priming effect that is sufficient to ensure a biphasic response to a second dose of hCG given 96 h later.
D000293:Adolescent; D000328:Adult; D000728:Androgens / Q000502:physiology; D002648:Child; D006063:Chorionic Gonadotropin / Q000008:administration & dosage / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007986:Luteinizing Hormone / Q000494:pharmacology*; D008297:Male; D013577:Syndrome; D013737:Testis / Q000378:metabolism*; D013739:Testosterone / Q000097:blood*; D013997:Time Factors
D000728:Androgens; D006063:Chorionic Gonadotropin; D013739:Testosterone; D007986:Luteinizing Hormone